Palisade Bio (PALI) logo

Palisade Bio (PALI) stock

Intestinal therapeutics , market cap $166M

After-hours Fri
$0.87
+3.58%

Close $0.84 -9.24%

Why is PALI down?

Down 25% over the five sessions to Nov 20 while the S&P 500 fell 9%.

  • Palisade Bio fell 25% in those sessions while biotech stocks fell a median 9%: it trailed its group by 16 points.

No SEC filing or news in our sources that week.

Sources: Price history, Nov 20, 2026

−3Long-term trend below a falling 200-day average, down over one year, down over two years

Tell me next time PALI moves

Free account, no card. An optional alert when PALI moves or its score changes.Pro, $1 for a first month. An optional alert when PALI moves or its score changes.Pro, 7 days free with a card. An optional alert when PALI moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on PALI →How the business stands, the timeline, and its peers, for Pro members.
Quality Score
-9
Poor
In its industry
#254of 273
Checks firing
0of 14
Trending down
From 52-week high
-70.6%
under its best in a year

PALI's Quality Score fell 1 point on Fri, Nov 20, to -9.

Follow PALI's trial news. Pro members can get an alert when Palisade Bio files news, and see its trials, share raises, and its CEO's filings.

Get an alert when PALI files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2026“…2 ASCENTRA-CD trial of PALI-2108 for the treatment of Crohn’s disease expected in the second half of 2026”Filing with regulators · SEC filing · Aug 10
Cash$114M, about 17 quarters (4.5 years) at the last year's spendingOn Sep 30

Key facts on PALI

Key facts on PALI
Holding it back28 times as many shares as a year ago
Latest filing8-K, Nov 10 Reported its quarterly results

What's next

Expected to report Tue Feb 9, after the close

After its last 3 reports it closed +0.9% on average, higher 2 of 3 times.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$114M, about 17 quarters (4.5 years) at the last year's spendingOn Sep 30

PALI catalysts

Coming up

4 more coming up, with sizes and sources, for Pro members.

What's next for PALI, and how long its cash lasts

Next step the company has named

2H 2026“IND for Phase 2 ASCENTRA-CD trial of PALI-2108 for the treatment of Crohn’s disease expected in the second half of 2026”Filing with regulators · SEC filing · Aug 10

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

Lead program
PALI-2108
Another trial
ASCENTRA-UCPhase 2 · Recruiting · 204 people · main data estimated Oct 2027 · NCT07845487

1 more trial, 5 more milestones and 28 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 17 quarters

$114M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed May 12, 2026)
  • At-the-market share sales program (S-3, filed May 12, 2026)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Director Robert Baltera Jr. bought 50,000 shares on Nov 17. 10 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and John Finley’s 11 filings and quotes.

Get an alert when PALI files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How PALI ranks in Biotech

PALI is #254 of 273 by Quality Score.

How PALI ranks in Biotech
RankStockQuality Score
254Palisade Bio (PALI) logoPALIPalisade Bio-9

More in Biotech

When does PALI report earnings, and what happens after?

Expected to report Tue Feb 9, after the close (in 80 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What PALI reported on Nov 10, 2026

The quarter

A loss of $0.07 a share, from $0.38.

“The increase primarily reflects expenses associated with advancing PALI-2108 into Phase 2 clinical development, including clinical trial start-up activities, manufacturing and clinical supply, and supporting preclinical and translational research, as well as higher employee-related expenses, including increased non-cash stock-based compensation expense.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

PALI's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The year-over-year increase reflects the Company’s expanded operating activities and higher employee-related expenses, including increased non-cash stock-based compensation expense.”

From its results filing (SEC filing · Nov 10)

The numbers

Market value
$166M
today
Sales
$500K
last 12 months

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on PALI: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-2.6%+1.9%+3.5%
May 12Aug 10Nov 10
ReportedGapReaction5
days
Nov 10, 2026After close-1.8%+3.5%-10.6%
Aug 10, 2026After close-2.4%+1.9%+2.4%
May 12, 2026After close0.0%-2.6%-5.7%

PALI closed higher after 2 of its last 3 reports.

PALI sales and profit by year

Sales and profit by year

Sales fell every year from 2017 to 2025, to $0. It lost money in each of the seven years.

Nothing is firing on PALI right now

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on PALI, and all 14 on every stock.Get in free →See the top 3 →Start Pro

PALI RSI on Nov 20: 24.6, below its 50-day and 200-day averages

Not scored

RSI 24.6, MACD below signal, below both averages. Not scored.

The deep dive on PALI

8 more findings on PALI, each with its source, for Pro members.

PALI share count over time

28 times the count a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of PALI outstanding, as filed
Shares
outstanding
As
of
179.3MNov 6, 2026
174.3MAug 6, 2026
173.6MMay 7, 2026
165.9MMar 18, 2026
Offerings, shelves, and splits of PALI, from its filings
From its
filings
Filed
Registered shares for a later sale (S-3)May 12, 2026
Raised $8,753 in a sale of sharesOct 2, 2025
Registered shares for sale (S-1)Sep 29, 2025
Registered shares for a later sale (S-3)Aug 15, 2025

6 more offerings on file, for Pro members.

PALI insider trades

2 insiders bought $329K across 9 filings, and 2 insiders sold $410K across 2 filings, in the last 6 months. The newest:

BuyRobert Baltera Jr.$50KDirectorat $1.01 on Nov 17, filed Nov 19

All 11 insider filings on PALI from the last six months, for Pro members.

All PALI insider trades

PALI's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

About Palisade Bio

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

14 employeesCarlsbad, CApalisadebio.com

What Palisade Bio says it competes with

“As a clinical biopharmaceutical company, we face competition from a wide array of companies in the pharmaceutical and biotechnology industries.”

From its annual report, SEC filing · Mar 20, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on PALI and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn PALI's score around: 8 things
  • 12 more filings explained, a plain line each
  • 5 more things pulling PALI's score down
BreakawayNov 19Robert Baltera Jr. bought PALI$50K at $1.01, filed Nov 19

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: PALI's Quality Score is -9 (Poor), #254 of 273 in Biotech. Insiders bought $329K and sold $410K in the last 6 months (Form 4).

What does PALI's Quality Score say?

PALI scores -9 today, which Breakaway calls Poor. It is #254 of 273 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 25% over the five sessions to Nov 20 while the S&P 500 fell 9%. Cash lasts about 17 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is PALI's Quality Score?

PALI scores -9 today, which Breakaway calls Poor (below zero). That is #254 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PALI's -9.

Are insiders buying PALI?

2 insiders bought $329K across 9 filings, and 2 insiders sold $410K across 2 filings, in the last 6 months. The newest is Robert Baltera Jr., Director, who bought $50K on Nov 17. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Palisade Bio: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.